首页> 外文期刊>Protein Expression and Purification >Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate
【24h】

Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate

机译:针对新的利什曼原虫临床分离株耐药基因的原核表达,纯化和多克隆抗体生产

获取原文
获取原文并翻译 | 示例
           

摘要

Diseases produced by protozoan parasites are one of the main causes of morbidity and mortality around the world, affecting millions of people. Among these, leishmaniasis has become the second most common cause of death and the problem is further complicated by the expansion of parasite resistance to the conventional drugs. The high rate of therapeutic failure thus calls for new rational approaches to develop alternative drugs. Understanding resistance mechanisms may help identify new targets for drug development. So we present here the cloning, expression, purification, and antibody production of a gene implicated in imparting resistance to pentavalent antimony (SbV) in clinical isolates of kala azar with a view to gain insight into the novel mechanism of its drug resistance. (C) 2005 Elsevier Inc. All rights reserved.
机译:原生动物寄生虫产生的疾病是全世界发病率和死亡率的主要原因之一,影响着数百万人。在这些当中,利什曼病已成为第二大最常见的死亡原因,并且由于对常规药物的寄生虫耐药性扩大,该问题进一步复杂化。因此,高治疗失败率要求开发替代药物的新的合理方法。了解耐药机制可能有助于确定药物开发的新目标。因此,我们在这里介绍了一种基因的克隆,表达,纯化和抗体产生,该基因与黑热病临床隔离株中的五价锑(SbV)产生抗性有关,以期深入了解其耐药性的新机制。 (C)2005 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号